ArticlePloS one2015
λ-Carrageenan P32 Is a Potent Inhibitor of Rabies Virus Infection.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- MG132-mediated inhibition of rabies virus replication via the Nrf2/SQSTM1/PINK1/Parkin autophagy pathway.Virology journal · 2026Article
- Avicenna's approach to the treatment of rabies in the perspective of current medicine.Wiener medizinische Wochenschrift (1946) · 2026Review
- In Vitro Antiviral Activity of Red Algae Extracts fromTropical medicine and infectious disease · 2026Article
- Andrographolide Inhibits Rabies Virus Replication.Transboundary and emerging diseases · 2026Article
- Article
- Comparative study of HIV-1 inhibition efficiency by carrageenans from red seaweeds familyHeliyon · 2024Article
- Sulfated Polysaccharides from Seaweeds: A Promising Strategy for Combatting Viral Diseases-A Review.Marine drugs · 2023Review
- Marine Bioactive Compounds Derived from Macroalgae as New Potential Players in Drug Delivery Systems: A Review.Pharmaceutics · 2022Review
- Advances in Research on Antiviral Activities of Sulfated Polysaccharides from Seaweeds.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Influence of the Structural Features of Carrageenans from Red Algae of the Far Eastern Seas on Their Antiviral Properties.Marine drugs · 2022Article
- Review
- New Insights into the Structure of Kappa/Beta-Carrageenan: A Novel Potential Inhibitor of HIV-1.International journal of molecular sciences · 2021Article
- Implications of Glycosaminoglycans on Viral Zoonotic Diseases.Diseases (Basel, Switzerland) · 2021Review
- Antiviral Activity of Carrageenans and Processing Implications.Marine drugs · 2021Review
- Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2.Scientific reports · 2021Article
- Carrageenan: Drug Delivery Systems and Other Biomedical Applications.Marine drugs · 2020Review
- Carrageenans as Broad-Spectrum Microbicides: Current Status and Challenges.Marine drugs · 2020Review
- Synthetic sulfonated derivatives of poly(allylamine hydrochloride) as inhibitors of human metapneumovirus.PloS one · 2019Article
- Marine Carbohydrate-Based Compounds with Medicinal Properties.Marine drugs · 2018Review
- Inhibition of Rabies Virus by 1,2,3,4,6-Penta-Viruses · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies, caused by rabies virus (RABV), is an acute, fatal encephalitic disease that affects many warm-blooded mammals. Currently, post-exposure prophylaxis regimens are effective for most rabies cases, but once the clinical signs of the disease appear, current treatment options become ineffective. Carrageenan has been reported as a potent inhibitor of many viruses. In this study, the λ-carrageenan (λ-CG) P32 was investigated for its potential role in inhibiting RABV infection. Our results show that P32 specifically inhibits the replication of several RABV strains but not vesicular stomatitis virus in multiple cell lines and shows low cytotoxicity. P32 mainly abrogated viral replication during the early stage of the post-adsorption period. Further studies demonstrated that P32 could affect not only viral internalization but also viral uncoating by blocking cell fusion mediated by RABV glycoprotein. Moreover, P32 can fully inhibit RABV infection in vitro during the post-adsorption period, whereas heparin and heparan sulfate, which possess similar structures to P32, showed significant but not complete inhibition of RABV infectivity. Collectively, our results indicate that λ-CG P32 is a promising agent that can inhibit RABV infection mainly by inhibiting viral internalization and glycoprotein-mediated cell fusion and can be used for the development of novel anti-RABV drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.